PDE5 inhibitors: breaking new grounds in the treatment of COVID-19.

Ryan VargheseGargi DigholkarJainam KarsiyaSahil SalviJeenam ShahDileep Kumar Rohit Sharma

Published in: Drug metabolism and personalized therapy (2023)

These benefits of PDE5 inhibitors make it a potential drug in the physicians' armamentarium in alleviating symptoms associated with SARS-CoV-2 infection. However, adequate clinical studies must be instituted to eliminate any untoward adverse events.

Keyphrases

coronavirus disease
sars cov
primary care
respiratory syndrome coronavirus
human health
depressive symptoms
climate change
drug induced
replacement therapy